Laurus Labs Q2 FY26 Profit Surges 20.2% to ₹194.97 Crore as Revenue Climbs 35.2% YoY

Mumbai, 23 October 2025: Laurus Labs Limited (NSE: LAURUSLABS, BSE: 540222) reported a 20.2% sequential increase in consolidated net profit to ₹194.97 crore for Q2 FY26, up from ₹161.08 crore in Q1 FY26. Year-on-year, profit jumped sharply from ₹19.84 crore in Q2 FY25, driven by strong performance across the formulation, Active Pharmaceutical Ingredients (API), and custom synthesis segments.

Headquartered in Hyderabad, Laurus Labs is an integrated pharmaceutical and biotechnology company engaged in the development, manufacturing, and sale of APIs, formulations, and contract synthesis services. Listed on NSE and BSE under LAURUSLABS, it serves clients across regulated international markets, combining research-led innovation with operational excellence.

Stock Trades at ₹943, Gains 2.07% Amid Robust Quarterly Results and Market Optimism

As of 3:30 p.m. IST, Laurus Labs’ share price was at ₹943, up ₹19.10 (2.07%) from the previous close of ₹923.90. The stock opened at ₹927.40, reached an intraday high of ₹943.00 and a low of ₹920.70, with a total traded volume of 41.21 lakh shares. The company’s market capitalisation stands at ₹50,905.49 crore, reflecting investor attention on strong operational performance.

Revenue from Operations Climbs 35.2% YoY to ₹1,653.47 Crore, Boosted by API and Formulation Segments

Laurus Labs’ total revenue for Q2 FY26 reached ₹1,653.47 crore, up 5.3% quarter-on-quarter and 35.2% year-on-year from ₹1,223.70 crore in Q2 FY25. Total income rose to ₹1,680.43 crore, a 6.4% sequential increase and 36.8% YoY gain, reflecting recovery in the company’s API and custom synthesis (CDMO) businesses and stronger formulation exports. Total expenses were ₹1,410.70 crore, higher than ₹1,205.49 crore a year ago due to increased material and employee costs, while finance costs moderated to ₹40 crore.

Profit Before Tax Skyrockets Over 10x YoY to ₹269.73 Crore, Driving EPS to ₹3.61

Profit before tax surged 1,082.4% YoY to ₹269.73 crore, up 20.3% sequentially, with net profit increasing 883% YoY. Earnings per share (EPS) for Q2 FY26 stood at ₹3.61, marking a 19.5% rise quarter-on-quarter and 876% increase YoY, underpinned by improved capacity utilisation and robust demand in contract manufacturing.

Half-Year Overview H1 FY26 Shows Net Profit Jumping Over 10x to ₹357.99 Crore

For the first six months of FY26, total income rose 34.5% YoY to ₹3,260.43 crore, while net profit increased from ₹32.35 crore to ₹357.99 crore, reflecting the turnaround in the company’s synthesis and formulation segments. EPS for H1 FY26 was ₹6.63, emphasising strong profitability and operational momentum.

Strengthened Balance Sheet with Equity Rising to ₹4,933.53 Crore and Borrowings Falling to ₹2,149.35 Crore

The company maintained a healthy balance sheet, with total assets at ₹9,415.25 crore, equity increasing to ₹4,933.53 crore, and borrowings reduced from ₹2,693.08 crore to ₹2,149.35 crore, indicating improved leverage. Cash and cash equivalents stood at ₹49.77 crore, while inventories were ₹2,020.96 crore, supporting continued operational growth.

Laurus Labs’ Q2 FY26 performance highlights a strong operational recovery and strategic growth across its API and formulation segments. With improved revenue, significant profit gains, and a strengthened balance sheet, the company demonstrates sustained financial discipline and scalability in its pharmaceutical and biotechnology operations.

REF: https://nsearchives.nseindia.com/corporate/LAURUSLABS_23102025152823_Outcome23102025.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations